Key result
Inhibitors of the VEGF signaling pathway are associated with cardiovascular complications such as arterial hypertension, requiring timely diagnosis and risk assessment before and during treatment.
This review outlines the mechanisms, diagnosis, risk assessment, and management of iatrogenic hypertension induced by VEGF inhibitors in cancer patients.
May prompt closer BP monitoring during VEGF inhibitor therapy; leaves open need for prospective management trials.
One of the key regulators of vascular tone is the vascular endothelial growth factor (VEGF), which can enhance the production of nitric oxide, a potent vasodilator, and reduce vascular resistance by generating new vessels. Both mechanisms contribute to blood pressure decrease. The implementation of a new class of antitumor therapy — inhibitors of VEGF signaling pathway — results in the growth of cardiovascular complications such as arterial hypertension (HTN). The paper analyzes the causes of HTN development, approaches to the timely diagnosis of HTN and the correct assessment of cardiovascular risk before administration of VEGF inhibitors and during the treatment. We also review the features of the approaches of elevated blood pressure management in patients receiving targeted therapy.
No takes yet. Share an insight, caveat, or question.
Kobalava et al. (2018) conducted a review in Hypertension related to VEGF inhibitors. VEGF inhibitors was evaluated. Inhibitors of the VEGF signaling pathway are associated with cardiovascular complications such as arterial hypertension, requiring timely diagnosis and risk assessment before and during treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: